Icatibant

Overview

Icatibant, sold as Firazyr, is a synthetic decapeptide that acts as a bradykinin B2 receptor antagonist. It is FDA-approved for the treatment of acute attacks of hereditary angioedema, or HAE, in adults. HAE is a rare genetic condition in which people experience recurrent episodes of severe swelling affecting areas such as the skin, abdomen, and airway.

A central feature of HAE attacks is the overproduction of bradykinin, a signaling molecule that increases blood vessel leakiness and drives the swelling. Icatibant is designed specifically to block bradykinin's action, addressing the immediate mechanism of an attack rather than the broader allergic pathways targeted by some other treatments.

Icatibant is formulated for subcutaneous injection and can be self-administered, which is significant because HAE attacks can be unpredictable and, when they involve the airway, potentially life-threatening. The ability to treat an attack promptly, including at home after appropriate training, is an important practical aspect of how the drug is used.

How it works

In hereditary angioedema, attacks are driven largely by excessive bradykinin, a peptide that binds the bradykinin B2 receptor on blood vessel walls. Activation of this receptor increases vascular permeability, allowing fluid to leak from the bloodstream into surrounding tissues and producing the characteristic swelling of an HAE attack.

Icatibant is a selective, competitive antagonist of the bradykinin B2 receptor. By binding to the receptor, it prevents bradykinin from exerting its effect, reducing the vascular leakage that causes swelling. Because it targets the receptor directly, its action does not depend on the underlying genetic deficiency that leads to excess bradykinin production in the first place.

This receptor-blocking mechanism makes icatibant an on-demand treatment aimed at resolving an attack already underway, rather than a preventive therapy taken continuously. Once administered, it works to halt and reverse the swelling associated with that specific episode. As the drug is cleared and an attack subsides, repeat dosing may sometimes be needed if symptoms persist or recur, according to the prescriber's instructions.

Clinical evidence

Icatibant was evaluated in the FAST clinical trial program, a series of studies in patients with hereditary angioedema. These trials examined the drug's effect on acute HAE attacks, assessing outcomes such as the time to the beginning of symptom relief compared with control treatment.

The FAST studies were central to establishing icatibant as an on-demand therapy for HAE attacks and informed its approval for self-administration. By focusing on how quickly and reliably the medication relieves the swelling of an acute episode, the program addressed the most pressing clinical need in HAE: stopping an attack, particularly one that could threaten the airway.

The evidence supports icatibant as an effective treatment for acute attacks in adults, while honest framing emphasizes what it does not do. It is not a cure for hereditary angioedema and does not prevent future attacks; people with HAE typically require a broader management plan that may include preventive therapies and an action plan for emergencies. Individual responses and the need for repeat dosing can vary.

Dosing & side effects

Icatibant is given as a subcutaneous injection to treat an acute HAE attack and may be self-administered by patients who have been trained to recognize attacks and use the medication. This guide does not provide doses or repeat-dosing intervals; those are determined by the prescriber and described in the product instructions, which patients should review carefully in advance of an attack.

The most common side effect is a reaction at the injection site, including redness, swelling, warmth, itching, or pain, which is usually temporary. Other reported effects can include dizziness and, less commonly, other systemic symptoms. Patients are advised to follow their clinician's guidance on what to do if symptoms do not improve or recur.

Because airway involvement in HAE can be dangerous, patients are typically counseled to seek emergency medical care for laryngeal or severe attacks even if they have self-administered icatibant. The medication treats the current attack and does not prevent future ones, so it is used within an overall HAE management plan developed with a specialist. Any severe or unexpected reaction warrants prompt medical attention.

Legal status

Icatibant is an approved prescription medication for acute hereditary angioedema attacks, available only through a licensed prescriber. It is not sold over the counter and is not a controlled substance. Because HAE attacks can be unpredictable and serious, it is often prescribed for patients to keep on hand and self-administer after appropriate training.

Regulatory labeling defines its approved indication and the patient population for which it is intended. Its use is generally overseen by clinicians familiar with hereditary angioedema, who help patients develop an action plan and decide when self-treatment is appropriate and when emergency care is needed.

Brand availability, generic options, and approved uses can vary by country and may change over time. Patients with HAE should rely on their specialist and pharmacist for current information about which products are available to them, how to administer the medication during an attack, and how it fits within their overall management plan.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema (FAST). N Engl J Med. 2010. Peer-reviewed study
2. Malbran A, Riedl M, Ritchie B, et al. Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial. Clin Exp Immunol. 2014. Peer-reviewed study
3. Šimac DV, Štimac T, Novak S. Is Icatibant Safe for the Treatment of Hereditary Angioedema During Pregnancy?. Curr Allergy Asthma Rep. 2022. Peer-reviewed study
4. Gras J. Icatibant for hereditary angioedema. Drugs Today (Barc). 2009. Peer-reviewed study
5. Cole SW, Lundquist LM. Icatibant for the treatment of hereditary angioedema. Ann Pharmacother. 2013. Peer-reviewed study
6. Maurer M, Aberer W, Caballero T, et al. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema. Clin Exp Allergy. 2022. Peer-reviewed study